Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has shown significant growth in Q3, with new business segments entering a harvest phase. The core business of home respiratory devices and cochlear implant components remains stable, with inventory pressures easing for downstream customers. The company achieved a strong performance in the first three quarters of 2024, with Q3 revenue reaching 450 million yuan, a year-on-year increase of 55.68% [1][2] - The diversified business layout initiated by the company is gradually entering a harvest period in 2024, particularly in the blood glucose management sector, where overseas B-end customer orders have been secured. The company is also focusing on high-end consumables in the in vitro diagnostics sector and making steady progress in cardiovascular technology development [1][2] Financial Performance Summary - For the first three quarters of 2024, the company reported operating revenue of 1.157 billion yuan (up 10.86% year-on-year) and a net profit attributable to the parent company of 258 million yuan (down 14.07% year-on-year). The net profit after deducting non-recurring gains and losses was 248 million yuan (down 11.15% year-on-year) [1] - The company expects revenues for 2024, 2025, and 2026 to be 1.693 billion yuan, 2.116 billion yuan, and 2.659 billion yuan, respectively, with year-on-year growth rates of 26.5%, 25.0%, and 25.7% [2][5] - The net profit attributable to the parent company is projected to be 397 million yuan, 505 million yuan, and 641 million yuan for 2024, 2025, and 2026, respectively, with corresponding growth rates of 26.6%, 27.3%, and 26.9% [2][5] Key Financial Metrics - The company’s gross margin is expected to remain stable around 41% over the forecast period, with a return on equity (ROE) projected to increase from 9.8% in 2023 to 13.6% in 2026 [2][6] - Earnings per share (EPS) are forecasted to be 0.98 yuan, 1.24 yuan, and 1.58 yuan for 2024, 2025, and 2026, respectively, with corresponding price-to-earnings (P/E) ratios decreasing from 47.79 to 22.17 over the same period [2][6]
美好医疗：三季度业绩增速显著，新赛道业务步入收获期